Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Allergan 3Q

Total specialty pharmaceuticals sales were up 5% in the quarter and medical devices sales increased 8%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Allergan 3Q

3Q Revenues: $1.2 billion (+6%)

3Q Loss: $668.7 million (earnings were $179.2 million in 3Q09)

YTD Revenues: $3.6 billion (+10%)

YTD Loss: $258.2 million (earnings were $401.0 million YTD09)

Comments: Total specialty pharmaceuticals sales were up 5% in the quarter and medical devices sales increased 8%. R&D expenses were $194.0 million (+10%). Results in the quarter include an aggregate charge of $369.1 million related to the impairment of Sanctura assets, as well as charges of $609.9 million for the global settlement with the DOJ related to marketing practices for certain therapeutic uses of Botox.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters